Exelixis
EXEL
#1816
Rank
โ‚น1.027 T
Marketcap
โ‚น3,834
Share price
-1.24%
Change (1 day)
19.16%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น220.89. In 2023 the company made an earnings per share (EPS) of โ‚น60.63 an increase over its 2022 EPS that were of โ‚น52.90.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น60.6314.61%
2022โ‚น52.90-22.97%
2021โ‚น68.68100%
2020โ‚น34.34-65.09%
2019โ‚น98.38-53.91%
2018โ‚น213.47333.96%
2017โ‚น49.19-260.61%
2016-โ‚น30.63-58.75%
2015-โ‚น74.25-42.45%
2014-โ‚น129.015.3%
2013-โ‚น122.51

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น1,034 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น126.23-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,330 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น191.67-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น678.16 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น275.65 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น349.72 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น340.62-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น77.96-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA